BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: BP-C1
Sponsor: Meabco A/S
Collaborators: Meddoc|Norwegian University of Life Sciences